Last reviewed · How we verify
GP plus placebo induction therapy — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
GP plus placebo induction therapy (GP plus placebo induction therapy) — Sun Yat-sen University. GP plus placebo induction therapy is an investigational treatment regimen that combines a primary active agent with placebo in an induction phase to evaluate therapeutic efficacy and safety.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GP plus placebo induction therapy TARGET | GP plus placebo induction therapy | Sun Yat-sen University | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GP plus placebo induction therapy CI watch — RSS
- GP plus placebo induction therapy CI watch — Atom
- GP plus placebo induction therapy CI watch — JSON
- GP plus placebo induction therapy alone — RSS
Cite this brief
Drug Landscape (2026). GP plus placebo induction therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/gp-plus-placebo-induction-therapy. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing